source
- Biohaven's ataxia drug resubmission accepted by FDA, shares surge 36%Biohaven’s experimental drug troriluzole, being developed for spinocerebellar ataxia, was previously rejected by the FDA because the agency questioned the design of the registrational trial. The co…
- Regulatory update: Hepatitis B hold lifted for Arbutus drug and Ultomiris receives accelerated approvalA regulatory update notes that the FDA has removed the clinical hold on Arbutus Biopharma's hepatitis B candidate, clearing the path for the company to resume development after a prolonged review.…